MedTrace Logo

A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma

NCT00658749 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2009-06-25

No results posted yet for this study

Summary

This is a phase one study to evaluate the safety, tolerability, and bioavailability of nebulized AIR645.

Conditions

Interventions

DRUG

AIR645

AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.

DRUG

Physiologic saline solution

Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.

Sponsors & Collaborators

  • Altair Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Mike Hodges, MD · Altair Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2009-04-30
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00658749 on ClinicalTrials.gov